Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > Bio Developments

Eurofins pumping $5m into a UK biopharmaceutical testing site

24-Mar-2017 - Eurofins will expand its UK biopharmaceutical testing offering through a £4m ($5m) facility in Livingston, Scotland.

US FDA fast-track designation for Humacyte's tissue-based hemodialysis product

22-Mar-2017 - Humacyte has received one of the first US FDA regenerative medicine designations for its investigational human acellular vessels (HAVs) candidate Humacyl.

Goodwin Biotech to work on opioid addiction vaccines project

22-Mar-2017 - Contract manufacturer Goodwin Biotechnology will work with Minneapolis Medical Research Foundation (MMRF) to develop vaccines to treat opioid addiction.

Lonza launches liver cells for biopharma research

17-Mar-2017 - Lonza has launched a new range of cryopreserved liver cells for biopharmaceutical companies that want to assess the toxicity of their drugs.

CDMO 3P selected to scale-up microbial production for Aussie biotech

14-Mar-2017 - Assuring anaerobic conditions in a fermenter design for aerobic organisms will be key in making Ondek’s Helicobacter pylori-based immunotherapy, says 3P Biopharmaceuticals.

Pfizer mulls sites for NC gene therapy plant year after Bamboo buy

10-Mar-2017 - Pfizer has confirmed it assessing potential sites in North Carolina for a gene therapy production plant.

Biodefense: Canada develops novel live virus smallpox vaccine from horsepox

07-Mar-2017 - Canada-based Tonix Pharmaceuticals has developed a novel live-virus vaccine for smallpox, which the firm claims is a safer alternative for biodefense stockpiles.

Kite public offering looks to raise $350m for CAR T cell therapy support

07-Mar-2017 - Kite Pharma has announced a public offering to support commercialisation of its lead CAR-based therapy, axicabtagene ciloleucel.

Vaxess granted $6m to develop sustained release vaccine patches

07-Mar-2017 - Two Bill & Melinda Gates Foundation grants will be used to develop a polio and measles rubella vaccine delivered through microneedles on a sustained-dermal patch.

Sartorius ups bioanalysis business with $320m Essen acquisition

03-Mar-2017 - Sartorius’ third acquisition in the bioanalysis space in the past year will add Essen BioScience’s real-time live-cell analysis platform to its portfolio.

UK makes validated stem cells available to therapy developers for £500 per vial

01-Mar-2017 - Cell therapy developers can source “regulator ready” stem cells from the UK Stem Cell Bank (UKSCB) for a £500 per vial fee under a scheme announced by the MHRA.

BioMarin building CA plant to support Factor VIII gene therapy candidate

28-Feb-2017 - A Californian manufacturing facility to support clinical development of a haemophilia A gene therapy will be completed this year, says BioMarin.

Sanofi and Lonza JV to build 200 person biologics facility in Visp

27-Feb-2017 - Sanofi and Lonza will construct a large-scale mammalian cell culture manufacturing site in Switzerland, with an initial investment of CHF 290m ($288m).

TxCell raises cash for first-in-man CAR-Treg cell therapy study

24-Feb-2017 - TxCell has raised €11m ($11.6m) through a share issue which it will use to fund first-in-man study of one of its cell therapy candidates.

LegoChem signs up Novimmune as latest ADC licensee

24-Feb-2017 - LegoChem Biosciences has teamed up with Novimmune to develop and test antibody drug conjugate (ADC) drug.

Ohr Pharmaceutical Inc. shuts sustained release tech lab

23-Feb-2017 - Ohr Pharmaceutical Inc. has halted activities at the laboratory in San Diego, California where research on its sustained release delivery technology was carried out.

CRB sister Discovery launches second antibody catalogue

21-Feb-2017 - Cambridge Research Biochemicals (CRB) has launched a second catalogue of research antibodies for academia, pharma and outsourcing firms.

Sanofi hires Selexis SA for three cell line development deals

21-Feb-2017 - Sanofi has contracted Swiss biotech Selexis SA to develop cell lines for a three early stage projects.

CellGenix GmbH starts work on cell therapy regent facility expansion

21-Feb-2017 - CellGenix GmbH has started expanding its cell and gene therapy reagents facility in Freiburg, Germany citing the progression of customer projects into clinical development and commercial launch.

Belgian CRO launches EU joint venture with Chromatography Institute

20-Feb-2017 - The Research Institute for Chromatography (RIC) and Anacura have joined forces to create anaRIC biologics, an R&D and GMP analytical specialist CRO for biologics.

Selecta hires Lonza to make synthetic vector delivered gene therapy

17-Feb-2017 - Selecta Biosciences Inc. has hired Swiss contractor Lonza to make a gene therapy candidate for the metabolic disease, Methylmalonic Acidemia (MMA).

TiGenix hires Lonza to make cell therapy for Crohn's disease complications

17-Feb-2017 - TiGenix is using Lonza as a US CMO and Takeda as an ex-US commercialization partner to launch and trial its off-the-shelf stem cell therapy for a complication of Crohn’s disease....

News in brief

Charles River Labs up on biologics services

17-Feb-2017 - Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.

Strategic CRO takes $100m hit from Pfizer's shelved PCSK9 candidate

17-Feb-2017 - Contract research organisation (CRO) ICON has taken a hit to its book-to-bill ratio after Pfizer dropped its anti-cholesterol candidate bococizumab in November.

Orgenesis granted €12.3m for GMP production ahead of clinical trials

14-Feb-2017 - Orgenesis’ Belgian subsidiary, Orgenesis SPRL, has received €12.3m ($12.8m) to further develop its Type 1 Diabetes program.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...